XML 52 R42.htm IDEA: XBRL DOCUMENT
v3.23.3

Commitments and Contingencies - Additional Information (Detail) |  |  |  | 1 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Aug. 21, 2023 USD ($) | Jun. 05, 2023 USD ($) | Apr. 18, 2023 USD ($) Agreement | Mar. 31, 2023 USD ($) | Feb. 28, 2023 USD ($) | Sep. 30, 2023 USD ($) shares | Dec. 31, 2022 USD ($)
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |
Long-term CVR derivative liability |  |  |  |  |  | $ 4,664,000 |
CVR derivative liability |  |  |  |  |  |  | $ 5,000,000
Number of separate agreements | Agreement |  |  | 2 |  |  |  |
Non GMP Manufacturing Services |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |
Cost of services as per agreement |  |  | $ 300,000 |  |  |  |
Clinical Supply Batch GMP Manufacturing |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |
Cost of services as per agreement |  |  | $ 200,000 |  |  |  |
Contingent Value Rights Agreement |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |
Percentage of excess cash on dispositions net |  |  |  |  |  | 100.00% |
Percentage of excess cash on dispositions net |  |  |  |  |  | $ 1,000,000 |
Percentage of excess preapproved costs |  |  |  |  |  | 100.00% |
Short-term CVR derivative liability |  |  |  |  |  |  | $ 5,000,000
Long-term CVR derivative liability |  |  |  |  | $ 4,500,000 |  |
CVR derivative liability |  |  |  |  |  | $ 0 |
Distribution to CVR holders from asset sale proceeds | $ 1,500,000 | $ 3,500,000 |  | $ 200,000 | $ 200,000 |  |
Related Party | Non GMP Manufacturing Services | Other Accrued Liabilities |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |
Future repayment obligation to related party |  |  |  |  |  | 300,000 |
GNI | Related Party | Non GMP Manufacturing Services |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |
Reimbursable development costs |  |  |  |  |  | $ 300,000 |
Vertex Asset Purchase Agreement | Contingent Value Rights Agreement |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |
Percentage of amount received on agreement, net of expenses |  |  |  |  |  | 100.00% |
F351 | GNI | Business Combination Agreement |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |
Termination fee required to pay upon termination of agreement |  |  |  |  |  | $ 2,000,000.0 |
F351 | GNI | Maximum | Business Combination Agreement |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |
Common stock, shares issued | shares |  |  |  |  |  | 1,110,776,224 |
Reimbursement for out-of-pocket fees and expenses |  |  |  |  |  | $ 2,000,000.0 |

X
- Definition Commitments and contingencies disclosure. + References No definition available. + Details
Name: | cbio_CommitmentsAndContingenciesDisclosureLineItems
Namespace Prefix: | cbio_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent value rights derivative liability. + References No definition available. + Details
Name: | cbio_ContingentValueRightsDerivativeLiability
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent value rights derivative liability current. + References No definition available. + Details
Name: | cbio_ContingentValueRightsDerivativeLiabilityCurrent
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent value rights derivative liability non current. + References No definition available. + Details
Name: | cbio_ContingentValueRightsDerivativeLiabilityNonCurrent
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cost of services as per agreement. + References No definition available. + Details
Name: | cbio_CostOfServicesAsPerAgreement
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Distribution from asset sale proceeds. + References No definition available. + Details
Name: | cbio_DistributionFromAssetSaleProceeds
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Excess amount retained from net proceeds related to disposition of assets. + References No definition available. + Details
Name: | cbio_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of separate agreements. + References No definition available. + Details
Name: | cbio_NumberOfSeparateAgreements
Namespace Prefix: | cbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of amount received on agreement, net of expenses. + References No definition available. + Details
Name: | cbio_PercentageOfAmountReceivedOnAgreementNetOfExpenses
Namespace Prefix: | cbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of excess cash on dispositions net. + References No definition available. + Details
Name: | cbio_PercentageOfExcessCashOnDispositionsNet
Namespace Prefix: | cbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of excess preapproved costs. + References No definition available. + Details
Name: | cbio_PercentageOfExcessPreapprovedCosts
Namespace Prefix: | cbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement for out-of-pocket fees and expenses. + References No definition available. + Details
Name: | cbio_ReimbursementForOutOfPocketFeesAndExpenses
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and development reimbursable costs. + References No definition available. + Details
Name: | cbio_ResearchAndDevelopmentReimbursableCosts
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Termination fee required to pay upon termination of agreement. + References No definition available. + Details
Name: | cbio_TerminationFeeRequiredToPayUponTerminationOfAgreement
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_OtherLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cbio_NonGMPManufacturingServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cbio_ClinicalSupplyBatchGMPManufacturingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=cbio_ContingentValueRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=cbio_OtherAccruedLiabilitiesCurrentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cbio_GNIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cbio_VertexAssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_FThreeFiveOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=cbio_BusinessCombinationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |